Eugene Schneider - 03 Jan 2022 Form 4 Insider Report for IONIS PHARMACEUTICALS INC (IONS)

Reporting relationship: EVP, Chf Clinical Develop Offc
Issuer ticker: IONS
Reported as of: 03 Jan 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Jan 2022, 17:00:05 UTC
Prior SEC filing: 19 Oct 2021
Next SEC filing: 19 Jan 2022
Source filing: View source filing
Reporting owner signature: By: Patrick R. O'Neil, attorney-in-fact For: Eugene Schneider

Key filing fact

Eugene Schneider filed Form 4 for IONIS PHARMACEUTICALS INC (IONS) on 05 Jan 2022.

Key facts

This page summarizes Eugene Schneider's Form 4 filing for IONIS PHARMACEUTICALS INC (IONS).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 05 Jan 2022, 17:00.

Change

Previous filing in this sequence was filed on 19 Oct 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IONS transaction Derivative

Non-Qualified Stock Option (right to buy)

Award

Transaction value: $0
Shares: +32,265
Change %
Price: $0.000000
Shares after: 32,265
Date: 03 Jan 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 32,265
Exercise price: $32.60
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Grant on 01/03/2022 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/03/2022. 25% of the shares subject to the option will vest and become exercisable on 01/03/2023. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.